Toshiba at EuroCIS: Empowering Retailers to “Create Your Tomorrow”
Attendees will experience solutions for secure, seamless, and personalized shopping
At EuroCIS 2025, Toshiba Global Commerce Solutions showcases how it empowers retailers with its innovative solutions portfolio for smart stores, customer personalization, and security (booth in hall 9 #B42). The international trade fair will take place on February 18-20 in Düsseldorf, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213535650/en/
The new TCx 820 all-in-one POS system is suitable for all types of store environments as it is available in various formats and screen sizes. (Photo: Business Wire)
“In a world brimming with possibilities, every retailer can shape their own future and deliver exceptional customer experiences and growth with the help of an experienced partner,” says Robin Lyon, Executive Director of Channels & Marketing, Toshiba Global Commerce Solutions. “To empower retailers to create their own tomorrow, Toshiba delivers complete solutions comprising of its modular MxP® hardware, software and services harnessing the power of AI, computer vision, and other transformative technologies. Advanced self-service solutions and new POS technologies are designed to meet the unique needs of retailers, no matter their size or segment.”
Innovative Solutions shown on the Toshiba booth
- Loss prevention and customer experience at self-checkout: The new Modular eXpansion Platform (MxP®) provides self-checkout solutions in a sleek design tailored for all retail segments. Various form factors feature capabilities for loss prevention and produce recognition using AI, computer vision and IoT sensors to recognize shrinkage and speed up transactions. Toshiba’s TCx® EDGEcam+ cameras monitor customer behaviors without in-store servers, enhancing security throughout the checkout area. For fast scan-free self-checkout, the MxP® VisionKiosk uses computer vision and AI to automatically identify items for a seamless shopping experience.
- Flexible POS-systems and versatile Touch Displays: The new TCx® 820 all-in-one POS-system and TCx® Touch Displays are available in multiple formats with a sleek design ready for all retail segments. They are configurable in five formats enabling seamless integration into any retail environment or use case. Screen sizes range from 10” to 24” with both landscape and portrait orientations available.
- Personalized shopping experiences: Catch Retail is an AI retail media platform for physical spaces, monetizing first-party data for retailers and brands, enabling them to reach new, targeted audiences in stores. Catch will demonstrate how they are revolutionizing in-store customer engagement, brand loyalty and revenue growth by enabling personalized media through various shopping touchpoints.
- AI-powered refrigeration management: Axiom Cloud will demonstrate how retailers can reduce energy consumption and save on maintenance costs in their cold chain operations using AI.
- Toshiba Commerce Marketplace: Aimed at meeting the ever-evolving needs of retail, the Toshiba Commerce Marketplace enables retailers to connect to an extensive network of industry-leading technology partners and solutions to stay competitive in an increasingly digital world, to enhancebusiness operations, and improve the shopping experience. Today, the Commerce Marketplace includes partners such as Adyen, Zebra, Datalogic, Ingenico, Ecrebo, Qualcomm, Honeywell, and Aptos, amongst others.
Toshiba will speak on the Blue and Red Stages
Toshiba experts will also share their knowledge and expertise on the EuroCIS stages:
February 18 at 11:40 - 12:00 on the Blue Stage (hall 10 G65)
The Business Benefits of Switching to a Secure Retail Cloud
Johnny Flynn, Retail Cloud Architect, Toshiba Global Commerce Solutions
February 19 at 14:00 - 14:20 on the Red Stage (hall 10 G01)
From Simple Break-Fix Maintenance to Sustainable Business Availability Management
Catherine Bataille, Director Professional Services, Toshiba Global Commerce Solutions
Dries de Beul, Technical Design & Solution Architect, Toshiba Global Commerce Solutions
To arrange to meet with Toshiba at EuroCIS, follow this link: Book a Meeting with Toshiba
About Toshiba Global Commerce Solutions:
Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs.
Visit commerce.toshiba.com and engage with us on:
LinkedIn - YouTube - Facebook - Instagram: @toshibacommerce
X/Twitter: @ToshibaCommerce
Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213535650/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom